Amit Kumar Acquires 5,000 Shares of Anixa Biosciences Inc (NASDAQ:ANIX) Stock

Anixa Biosciences Inc (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar acquired 5,000 shares of the stock in a transaction on Friday, July 11th. The stock was purchased at an average cost of $3.15 per share, with a total value of $15,750.00. Following the transaction, the chief executive officer directly owned 574,925 shares of the company's stock, valued at $1,811,013.75. This represents a 0.88% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Amit Kumar also recently made the following trade(s):

• On Wednesday, June 4th, Amit Kumar bought 10,000 shares of Anixa Biosciences stock. The shares were acquired at an average price of $2.85 per share, with a total value of $28,500.00.

Anixa Biosciences Stock Down 0.4%

ANIX stock traded down $0.01 during mid-day trading on Wednesday, reaching $3.19. The company had a trading volume of 42,483 shares, compared to its average volume of 104,939. The stock has a market capitalization of $102.62 million, a P/E ratio of -8.38 and a beta of 0.39. Anixa Biosciences Inc has a one year low of $2.07 and a one year high of $4.20. The stock's 50-day simple moving average is $3.02 and its two-hundred day simple moving average is $2.87.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last issued its quarterly earnings data on Tuesday, June 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.01. On average, research analysts forecast that Anixa Biosciences Inc will post -0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC raised its position in Anixa Biosciences by 36.5% in the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock worth $34,000 after acquiring an additional 3,900 shares in the last quarter. Millennium Management LLC bought a new stake in Anixa Biosciences in the fourth quarter worth about $26,000. LPL Financial LLC raised its position in Anixa Biosciences by 37.2% in the fourth quarter. LPL Financial LLC now owns 42,937 shares of the company's stock worth $100,000 after acquiring an additional 11,633 shares in the last quarter. Private Advisor Group LLC bought a new stake in Anixa Biosciences in the first quarter worth about $35,000. Finally, Jane Street Group LLC bought a new stake in Anixa Biosciences in the fourth quarter worth about $67,000. 29.13% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ANIX has been the subject of several research analyst reports. Wall Street Zen raised Anixa Biosciences from a "sell" rating to a "hold" rating in a report on Friday, June 6th. Maxim Group began coverage on Anixa Biosciences in a research note on Friday, March 21st. They set a "buy" rating and a $10.00 price objective on the stock. HC Wainwright restated a "buy" rating and set a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, March 25th. Finally, D. Boral Capital restated a "buy" rating and set a $10.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, June 10th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $9.00.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.